JNJ-55308942
Showing 1 - 25 of 420
Bipolar Disorder Trial in Worldwide (JNJ-55308942, Placebo)
Recruiting
- Bipolar Disorder
- JNJ-55308942
- Placebo
-
Huntsville, Alabama
- +45 more
Aug 17, 2022
Healthy Trial in Leuven (JNJ-55308942, [18F]-JNJ-64413739)
Completed
- Healthy
- JNJ-55308942
- [18F]-JNJ-64413739
-
Leuven, BelgiumUZ Leuven Gasthuisberg
Jan 18, 2019
Healthy Trial in Merksem (JNJ-55308942 High Dose, JNJ-55308942 Low Dose, Levonorgestrel/Ethinyl Estradiol Fixed Dose combination
Completed
- Healthy
- JNJ-55308942 High Dose
- +3 more
-
Merksem, BelgiumClinical Pharmacology Unit
Sep 27, 2018
Healthy Trial in Merksem (JNJ-55308942 0.5 mg, JNJ-55308942 1.5 mg, JNJ-55308942 4 mg)
Completed
- Healthy
- JNJ-55308942 0.5 mg
- +8 more
-
Merksem, BelgiumClinical Pharmacology Unit
Apr 17, 2018
Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)
Not yet recruiting
- Advanced Prostate Cancer
-
Lyon, France
- +2 more
Oct 18, 2023
Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)
Not yet recruiting
- Myeloproliferative Disorders
- +3 more
- (no location specified)
Nov 21, 2023
Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Los Angeles, California
- +6 more
Jan 18, 2023
Metastatic Castration-resistant Prostate Tumors Trial in Australia, Korea, Republic of, United States (JNJ-78278343, Cetrelimab)
Not yet recruiting
- Metastatic Castration-resistant Prostate Neoplasms
-
Sarasota, Florida
- +7 more
Apr 6, 2023
Multiple Myeloma Trial in Belgium, Israel, Spain (Daratumumab, JNJ-63723283)
Completed
- Multiple Myeloma
-
Antwerpen, Belgium
- +12 more
Dec 1, 2022
Healthy Trial in Leiden (JNJ-69095897, Placebo)
Recruiting
- Healthy
- JNJ-69095897
- Placebo
-
Leiden, NetherlandsCentre for Human Drug Research
Jan 31, 2023
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (JNJ-79635322)
Recruiting
- Relapsed or Refractory Multiple Myeloma
-
Edegem, Belgium
- +16 more
Jan 27, 2023
Multiple Myeloma Trial in Japan, United States (JNJ-68284528)
Completed
- Multiple Myeloma
- JNJ-68284528
-
Phoenix, Arizona
- +20 more
Oct 5, 2022
Carcinoma, Non-small-Cell Lung Trial in New York, Fairfax (JNJ-86974680, Cetrelimab, Radiation Therapy)
Recruiting
- Carcinoma, Non-small-Cell Lung
- JNJ-86974680
- +2 more
-
New York, New York
- +1 more
Nov 8, 2023
Geographic Atrophy, Macular Degeneration Trial in United States (JNJ-81201887, Prednisone, Placebo)
Recruiting
- Geographic Atrophy
- Macular Degeneration
- JNJ-81201887
- +4 more
-
Phoenix, Arizona
- +3 more
Mar 31, 2023